Founder in Residence, Priming plant resilience for climate risks
加入我们建设:我们正在寻找具有深入技术和商业领域专业知识的创业精神的人,他们渴望通过风险构建解决紧急未满足挑战。这个角色提供了一个独特的机会,以在 agtech 前沿工作,领导一个公司解决气候适应性问题食品安全和更广泛的生物经济。该职位是全日制的工作,最初直到企业合并和转型 (大约2027年第二季度末),地点 TBD. ABOUT DSV Deep Science Ventures (DSV) 在创造人类和地球都能勃发展的未来的使命上。我们利用我们独特的创业过程来创造,转型和投资科学公司,将现有的科学知识与创始人类型的科学家结合成具有高影响力的企业。在四个部门制药,气候,农业和计算领域开展业务,通过采取第一原则方法和与领先机构合作,我们应对这些领域定义的挑战。我们的伙伴关系与文艺复兴慈善:促进农作物复原性,DSV 与文艺新兴慈善合作以加速创建风险的发展,在气候风险,植物生物学和可部署的农产品交叉点。关于角色你将作为 DSV 创建风險计划的创始人加入并与 DSV 和文艺新世纪慈善团队密切合作,推出新的公司。在该项目期间,你将完善,改进和补充现有范围工作:· 对种植系统的技术论文,可以为日益不可预测和严重的气候压力 (忽视和技术易处理)应对抗药物能力做好准备;·商业忽视 (IP 战略,差异化,竞争); ·价值提案 (市场,价值捕获,技术经济学); ·监管策略和定位;·筹款策略和投资;·优化公司的策略以实现最快速且低风险的 A 系列。准备投资委员会 (IC) 将需要满足我们的投资标准,招募咨询和联合创始团队成员,并同时筹集额外扩张基金。假设你在 IC 取得成功,将于2027年2季度底获得预种子投资和 spin-out.
查看英文原文
Join us to build: we’re seeking entrepreneurially-minded individuals with deep technical and commercial domain expertise, who are eager to solve urgent unmet challenges through venture building. This role offers a unique opportunity to work at the forefront of agtech, leading a company solving challenges of climate adaptation for food security and the wider bioeconomy.
The role is full-time, remoteinitially until venture incorporation and spin-out (circa end of Q2 2027), location TBD.
ABOUT DSV
Deep Science Ventures (DSV) is on a mission to create a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out, and invest in science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. Operating in four sectors—Pharmaceuticals, Climate, Agriculture, and Computation—we tackle the challenges defining these areas by taking a first principles approach and partnering with leading institutions.
OUR PARTNERSHIP WITH RENAISSANCE PHILANTHROPY
Driven by mutual conviction in the huge unmet need for driving a new category of agricultural technology: priming resilience in crops,DSV has partnered with Renaissance Philanthropy to accelerate the development of venture creation at the intersection of climate risk, plant biology, and deployable agricultural products.
ABOUT THE ROLE
You will join DSV’s venture creation programme as a Founder-in-Residence and work closely with the DSV and Renaissance Philanthropy team to spin out the new company. During the programme you will refine, improve and complement existing scoping work on:
- The technical thesis for crop systems that can be primed for resilience in the face of increasingly unpredictable and severe climate pressures (neglect and technical tractability);
- Commercial neglect (IP strategy, differentiation, competition);
- Value proposition (market, value capture, techno-economics);
- Regulatory strategy & positioning;
- Fundraising strategy & pitching;
- Optimising company strategy for the most rapid and de-risked path to Series A.
Preparation for Investment Committee (IC) will involve fulfilling our investment criteria, recruiting advisory and co-founding team members, and parallel fundraising for additional expansion funds.
Assuming success at IC, you will receive pre-seed investment and spinout the company by the end of Q2 2027. You and your co-founders will own a significant stake in the business and continue receiving support post-spinout.
THE OPPORTUNITY
Across global agriculture, climate volatility is no longer a ‘once-a-decade’ disruption - it is becoming an in-season operating condition. Drought and heatwaves are already driving severe regional harvest losses, with cascading impacts that reach far beyond the farm gate: price shocks, food insecurity, and destabilised livelihoods. Even where catastrophic crop failures are not occurring, the evidence base is clear that climate change is already depressing yields and amplifying climate-related production losses in major cropping systems.
Despite this reality, most crop resilience strategies remain anchored in a static view of risk. Today’s dominant approaches focus on breeding or engineering permanent stress tolerance into plants, or introducing permanent protective structures. While effective under chronic stress, these solutions come with an inherent trade-off: technologies that protect yield under adverse conditions present a burden when conditions are favourable. For many crops - particularly rain-fed cereals and broadacre systems - this ‘carrying cost’ is economically unacceptable. In practice, growers are left exposed to short, acute stress events (such as a brief heat spike during flowering or sudden water-logging after planting) that can irreversibly damage yield but do not justify permanent genetic or infrastructure compromises.
We believe this creates a compelling opportunity for a new paradigm: on-demand plant resilience. Instead of locking crops into a constant defensive state, plants could be temporarily primed to withstand stress only when risk is imminent - and then returned to a high-productivity mode once the threat passes. Advances across plant biology now make this vision increasingly plausible. Emerging tools such as RNA-based interventions, virus-enabled gene modulation, signalling peptides, and stress-responsive biologicals point toward the ability to transiently activate protective pathways, reprogram development, or stabilise yield-critical processes during vulnerable windows.
This approach has the potential to address not only extreme climate shocks, but also the everyday volatility that quietly erodes agricultural value: mistimed flowering, pre-harvest sprouting triggered by humidity, transient root-zone stress, or short droughts that reduce grain fill. Importantly, these interventions could be deployed in-season, aligned with weather forecasts or early stress signals, creating a more adaptive and responsive crop protection toolkit.
Commercially, this space remains wide open. Existing biostimulants and stress-mitigation products are often blunt, inconsistently effective, or poorly matched to specific climate risks. Meanwhile, large incumbents remain focused on conventional chemistry, genetics, or incremental biologicals, leaving little coordinated effort around truly inducible resilience platforms. At the same time, regulatory and technical signals show growing feasibility for novel biological and RNA-based crop inputs, while grower demand for tools that protect yield reliability under volatility continues to accelerate.
We are seeking a Founder in Residence to build a company at the intersection of climate risk, plant biology, and deployable agricultural products. The ambition is to create a platform that makes climate readiness a controllable, on-demand trait - integrating scientific insight, smart delivery, and clear grower ROI into a scalable venture capable of redefining how crops are protected in an unpredictable world.
Requirements
WHO SHOULD APPLY
Essential Values
- You are highly motivated by unsolved challenges in climate risk mitigation, and driven to challenge the status quo in agriculture.
- You are impact driven, take the initiative, make things happen, and think from a first principles perspective to figure out what’s really needed.
- You have clear entrepreneurial spirit and mindset, demonstrated through impactful innovation, and an ability to work in ambiguous, unstructured but fast-paced, demanding and pressurised environments.
- Collaborative nature, with the ability to work effectively in cross-functional teams.
Essential experience (must-have)
- Core science depth (PhD or equivalent industry R&D know-how) in plant physiology, crop science, molecular biology, epigenetics, microbiology (or similar), with knowledge breadth across technological areas relevant for priming plant resilience such as:
- Delivery systems for biologicals (e.g. nanoparticle design, encapsulation chemistry, triggered release mechanisms, protectant formulations);
- Developmental regulation & priming (e.g. RNA / peptide-based modulators, epigenetic modification, heat shock pathways, hormone signalling);
- Plant-microbiome engineering (e.g. symbiont characterisation, consortia design, engineered exudate production, host-microbe signalling);
- Accelerated trait development & gene editing (e.g. tissue regeneration protocols, wild relative introgression, precision breeding pipelines);
- Crop environment engineering (e.g. seed/root coating formulations, biodegradable matrices, water management at plant scale).
- Translational execution: e.g. taking traits / actives from discovery to field, managing CRO/CDMO programs, building regulator / investor / customer-ready data packages; and / or partnership development (growers, CROs/CDMOs, suppliers) and scalable IP strategy.
- Cross-functional ownership across: R&D - Product - Regulatory - IP, evidenced by shipped results (trial outcomes, submissions, patents, launches); and / or design of pivotal field trials.
- Venture creation/fundraising; and/or product leadership in agtech / biotech or adjacent areas.
Equivalents considered: deep industry R&D in agtech / biotech or a PhD with applied field work and comparable outcomes.
Preferred experience (nice-to-have)
- Previous Founder experience (in biotech).
- Previous C-suite experience (in biotech).
- Previous fundraising experience (VC).
- Commercial & BD expertise incl. network in agrochem/pesticide development (licensing, partnering, collaborations).
- Strong track record of building and leading successful teams.
Benefits
OUR OFFER
By joining DSV, you’ll be joining a team of operators who have founded companies and led translation of science at some of the most respected universities, charities, funds and government agencies. 2/3 of the team have founded or led a company at C-suite and 65% have a PhD. Our team dedicate several hours every week to each Founder or founding team to provide tailored guidance, resources and feedback covering every aspect of what it takes to successfully launch a new venture from both the tech and commercial perspectives:
- We provide optimised, purpose-built, proprietary tools, resources and processes to help create high-impact ventures from scratch, using our venture creation methodology.
- DSV and RenPhil's extensive network incl. leaders of biotech VCs, technical & commercial domain expertise, and wide-ranging portfolio company capabilities.
- We jointly provide an initial £250k (~$340k / €290k) investment governed by our Investment Committee to incorporate the new venture and develop early proof-of-concept data that is often needed to attract high profile non-venture studio VCs. This funding is also key for obtaining grant funding, which often needs to be matched with private investment.
- You and your co-founder(s) together will own the majority equity stake in the company.
- We provide minimum guaranteed income of £4,166 per month (fixed), paid to each Founder as a consultancy fee until the company is launched and pre-seed investment is secured.
- We provide continuous support post spin-out, including fundraising, commercial partnerships, recruitment and team-building (amongst other things).
- Other Founders currently at DSV across sectors working collaboratively and supporting one another - a unique resource to draw on.
Originally posted on Himalayas